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ABSTRACT
Purpose The purpose of this study was to investigate the impact of risk communication about bisphosphonate (BP)-related osteonecrosis
of the jaw (ONJ) on the number of reported cases to the Drug Adverse Reactions Reporting System and on the incidence proportion of ONJ
in a hospital-based cohort study in Japan.
Method We conducted a survey of the safety information on BP-related ONJ available from regulatory authorities, pharmaceutical
manufacturers and academic associations. We also performed a trend analysis of a dataset from the Drug Adverse Reactions Reporting
System and a sub-analysis, using previously constructed data from a retrospective cohort study.
Results Risk communication from pharmaceutical manufacturers and academic associations began within 1 year after revisions were made
to the package inserts, in October 2006. Twenty times more cases of ONJ have been reported to regulatory authority since 2007, compared
with the period before 2007. In our cohort, the incidence proportion of ONJ during and after 2009 was four times greater than before 2009.
During this period, BPs were frequently prescribed, whereas there was no increase in the use of alternative agents, such as selective estrogen
receptor modulators.
Conclusion ONJ was increasingly diagnosed after risk communication efforts, but the impact of the communications was not clear. Safety
notifications were diligently disseminated after the package insert was revised. However, there was no surveillance for ONJ before the
revision. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
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INTRODUCTION
Osteonecrosis of the jaw (ONJ), also called osteomye-
litis of the jaw, is defined as the presence of exposed
bone in the maxillofacial region that does not heal
within 8 weeks.1–3 ONJ has received increasing
attention since case reports about patients exposed to
bisphosphonates (BPs) were published in 2003.4,5 In
the United States of America (USA), regulatory
authorities first indicated safety concerns about
zoledronic acid and pamidronate with regard to
osteonecrosis in 2003.6 In 2004, the manufacturer of
zoledronic acid revised the package insert in the USA
and issued a “Dear Health Professional” letter.7 Safety
notifications regarding osteonecrosis were issued in
other regions, such as Canada, Australia, New Zealand7
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and Japan, in 2004 and 2005. Early case reports were
followed by the publication of epidemiological studies
in 2005 and 2006.8–10 Thereafter, position papers,11
guidelines12 and expert panel recommendations3,13
were published in 2006 and 2007. Some of these papers
cautioned patients receiving oral BPs.3,11,13 The risk of
ONJ for patients receiving oral BPs was considered
much lower than the risk for patients receiving intrave-
nous BPs.11,13 However, the incidence proportion of
an adverse reaction was not fully studied until later,
when the risk associated with oral BPs was proved to
be smaller than that for intravenous BPs.14,15
Although dissemination of safety information to
health care professionals or patients is the most com-
mon method for minimizing risk when a novel safety
concern is discovered, the impact of risk communica-
tion has remained unknown and cannot be guaranteed
to result in the intended effect.16,17 Few studies have
addressed the long-term impact of risk communication
on the incidence of adverse events and whether
adverse events have been successfully reduced. Instead,
the impact of risk communication is often assessed by
measuring processes such as changes in drug use and
by laboratory monitoring.17 Because ONJ is uncommon
in the general population and its background incidence
rate is low, we attributed an increase in disease reports
to greater recognition of the disease among BP-exposed
patients after risk communication, if the characteristics
of the patients and the use of BPs did not change substan-
tially. We expected that the risk communication initiative
would decrease the incidence proportion of ONJ among
BP-exposed patients, after a temporary increase.
The purpose of this study was to investigate the
impact of risk communication on oral BP-related
ONJ in Japan; on the number of reported cases to
the Japanese regulatory authority, the Drug Adverse
Reactions Reporting System of the Pharmaceuticals
and Medical Devices Agency (PMDA); and on the
incidence proportion of ONJ in a hospital-based
cohort study of 6923 osteoporosis patients at Kyoto
University Hospital.
METHODS
We surveyed safety information about oral BP-related
ONJ that was produced by the PMDA, pharmaceutical
manufacturers and academic associations. We also
conducted a trend analysis of a dataset from the Drug
Adverse Reactions Reporting System of the PMDA
and a sub-analysis, using the previously constructed
data from a retrospective cohort study that was
conducted at Kyoto University Hospital from February
2011 to July 2012.18 The protocol was approved
by the Ethical Committee of the Graduate School of
Medicine, Kyoto University (E1445).
Risk communication regarding oral BP-related ONJ
First, we surveyed the safety information from the
PMDA by searching the PMDA Web site for the
words “jaw” or “BPs” (accessed June to July 2012).
We extracted articles on periodic safety information
and letters and guidance publications, and we listed
the relevant information after removing duplicate
information. Second, we surveyed the types of risk
communication materials concerning oral BP-related
ONJ that were released by manufacturers marketing
oral BPs in Japan and how and when they were dis-
seminated. Two pharmaceutical companies collected
letters and guidelines from the 10 manufacturers
marketing oral BPs in Japan between July 2012 and Jan-
uary 2013. Finally, we collected information on the risk
communications materials (type, timing of dissemina-
tion and method of dissemination) that were released
by two academic associations (the Japanese Society of
Oral and Maxillofacial Surgeons and the Japanese
Society for Bone and Mineral Research) between
July and August 2012. One of the authors, a medical
doctor, reviewed the collected communications mate-
rials and summarized the warnings and recommenda-
tions announced in the communications.
Reported cases of ONJ to the regulatory authority
A dataset containing the adverse drug reactions
reported to the Drug Adverse Reactions Reporting
System of the PMDA between April 2004 and
December 2011 was downloaded, and the cases of
ONJ suspected to be adverse reactions to osteoporosis
medications (including oral BPs) were counted. We
used the preferred terms in the Standardized Medical
Dictionary for Regulatory Activities (MedDRA)
Queries for “osteonecrosis,” with the exception of
anatomically irrelevant terms, to retrieve the cases of
ONJ. The list of drugs included in this study is shown
in Appendix 1.
Cohort study
We conducted a cohort study of outpatients and inpa-
tients who were diagnosed with osteoporosis, using
the International Classification of Diseases (ICD-10)
code (Appendix 2), and who received at least one
prescription for an osteoporosis medication at Kyoto
University Hospital during a study period (November
2000 to October 2010).18 The exclusion criteria were
as follows: age younger than 20 years old; primary or
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metastatic tumors in the maxillofacial region; history
of trauma or radiation therapy in the maxillofacial
region; and intravenous treatment with BPs.
We extracted the clinical data from the electronic
medical records (EMRs) using an EMR retrieval
system.19 This system retrieves electronic data for
outpatients and inpatients at Kyoto University
Hospital, including demographic data, diagnoses and
ICD-10 codes, medications and injections, laboratory
tests and radiological and pathological studies. The me-
dian duration of oral BP administration, co-medications
and comorbid conditions were also extracted using the
EMR retrieval system.
The medications administered for osteoporosis be-
tween November 2000 and October 2010 in this cohort
were collected by the retrieval system. The list of drugs
included in the cohort study is shown in Appendix 3.
The numbers of BP users, estrogen users and other
osteoporosis drug(s) users in the cohort were calculated
for each year, counting patients who were prescribed
medications at least once during that year, regardless
of the use of other osteoporosis medications.
To identify relevant ONJ cases, we reviewed the ra-
diographic imaging and clinical records of the patients
with a diagnosis of not only ONJ but also inflammatory
conditions of the jaw that were possibly related to ONJ,
as specified by the ICD-10 codes (Appendix 4). The di-
agnostic criteria were detailed in a previous report.18
Briefly, ONJ was diagnosed independently by two oral
and maxillofacial surgeons in accordance with the
proposed criteria, using the findings from panoramic
X-rays, technetium bone scans, computed tomography,
histological images or surgery. We grouped the cases
of osteomyelitis of the jaw with ONJ because we
considered it difficult to distinguish between these two
diseases. The radiographic findings for jawbone infec-
tions in patients treated with BPs are similar to those
for ONJ related to BPs,20–22 and the presence of
osteonecrosis is a common histopathologic finding, both
in ONJ and in osteomyelitis of the jaw related to BPs.23
The incidence proportion of confirmedONJwas defined
as the number of manually confirmed, newly developed
ONJ cases in the cohort (e.g., BP group or non-BP group)
in 2000–2002, 2003–2004, 2005–2006, 2007–2008 and
2009–2010, divided by the size of the cohort for each 2-
or 3-year period. The BP group included the patients who
were prescribed BPs at least once during the period and/
or in the past, regardless of the use of other osteoporosis
medications; the non-BP group included the patients who
were prescribed osteoporosis medication(s) other than
BPs and those who had never been prescribed BPs.
The distinction between BP users in the drug use
survey and the BP group in the incidence proportion
survey was as follows: we classified a patient who
received both BPs and estrogen in the same year as
one BP user and one estrogen user over the same time
period in the drug use survey. However, we classified
the patient into the BP group rather than the non-BP
group in the incidence proportion survey. This distinc-
tion was made because the impact of osteoporosis
medications other than BPs on the incidence propor-
tion of ONJ was considered to be negligible.
We evaluated the proportions of the cases recorded as in-
flammatory conditions of the jaw and alveolitis of the jaw
(specified by ICD-10 codes K10.2, K10.3 and K10.0
[Appendix 4] in the EMR); the proportions were defined
as the number of newly recorded cases of the inflammatory
condition of the jaw in the EMRs of the cohort (e.g., BP
users or non-BP users) during each 2- or 3-year period, di-
vided by the size of the cohort during the period.
RESULTS
Risk communication regarding oral BP-related ONJ
The risk communication materials regarding oral BP-
related ONJ, released by the PMDA, pharmaceutical
manufacturers and academic associations, are listed in
Table 1. The pharmaceutical manufacturers revised the
package inserts in October 2006. The case reports or
epidemiological studies regarding ONJ were published
after the package insert was revised. Six separate but
overlapping guidance announcements, in addition to
the package insert, were issued. An academic associa-
tion held educational meetings for health professionals
and patients during their annual meeting in April 2008.
Reported cases of ONJ to the regulatory authority
An increasing number of cases of ONJ that were
suspected adverse reactions to oral BPs were reported
to the PMDA after 2007, immediately after the safety
information was disseminated (Figure 1). These cases
included those with a past history of ONJ (that is, cases
of ONJ that occurred earlier were reported as cases of
ONJ after 2004 in the system). There were nearly 20
times more reported cases of ONJ during and after
2007, compared with the number of cases during and
before 2006. Reported cases of ONJ that are suspected
to have been adverse reactions to osteoporosis medica-
tions other than BPs have been rare. For reference, the
estimated numbers of patients taking oral BPs in Japan
were 2 082928 in 2007 and 2 470 979 in 2008.24
Cohort study
The cohort consisted of 6923 osteoporosis patients;
4129 were prescribed oral BPs (59.6%; mean age,
risk communication and incidence proportion of osteonecrosis of jaw
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65.0), and 2794 patients received other osteoporosis
drugs (40.3%; mean age, 65.5). The median durations
of administration were 364.0 days for BPs and
439.5 days for other osteoporosis drugs. For the BP
group and the other osteoporosis drugs group, the
numbers of patients using concomitant steroids were
2934 (71.0%) and 1508 (53.9%), respectively; the
numbers of patients treated with anti-cancer drugs
were 551 (13.3%) and 256 (9.1%), respectively; and
the numbers of patients with diabetes were 707
(17.1%) and 442 (15.8%), respectively.18
The number of BP users has been increasing steadily
since 2000 (Figure 2). The number of estrogen users, in-
cluding users of selective estrogen receptor modulators,
has been low. The number of users of other osteoporosis
medications, including active vitamin D3 or calcium,
Table 1. Risk communication about oral BP-related ONJ in Japan
Date* Organization Content
Oct. 2006 PMDA†, pharmaceutical
manufacturers
Measure: revised package insert for alendronate and risedronate
“ONJ has been reported in patients receiving bisphosphonates. The majority of reported cases have been
associated with dental procedures, such as tooth extraction, or with local infection. Physicians should fully
disclose the adverse reactions to their patients and observe them closely.”
Jan. 2007 pharmaceutical
manufacturers
Notices to hospitals and “Dear Health Professional” letters to inform them about the content of the revised
package insert
June 2007 academic association Publication of a case report33
There was one case of osteoporosis diagnosed with oral BP-related ONJ; the other case, a case of multiple
myeloma, was diagnosed with iv BP-related ONJ.
Sep. 2007 PMDA, pharmaceutical
manufacturers
Measure: revised package insert for etidronate
Oct. 2007 academic association Publication of an observational study34
Questionnaires were sent to 239 institutions, and 30 patients with osteonecrosis were reported. Of them, 20
patients received iv BPs, eight received oral BPs and one received both.
Jan. 2008 academic association News article entitled “osteonecrosis of the jaws induced by anti-osteoporosis treatment”
“Patients on BP therapy requiring dental procedures should tell their dentists that they are being treated with
BPs, and physicians should fully explain the adverse reactions to their patients when prescribing BPs.”
Jan. 2008 academic association,
pharmaceutical manufacturers
Announcement of a guidance publication, entitled “Bisphosphonates and osteonecrosis of the jaw”
A 20-page pamphlet, with the diagnostic criteria, clinical manifestations, risk factors and epidemiology of iv
and oral BP-related osteonecrosis of the jaw and instructions for physicians, pharmacists, dentists and oral
surgeons
Mar. 2008 academic association Announcement of guidance publication, entitled “management of patients on BP therapy”
A four-page pamphlet with the diagnostic criteria, management, risk factors, epidemiology of iv and oral BP-
related osteonecrosis of the jaw and instructions for physicians, dentists and oral surgeons
Apr. 2008 academic association Public meeting for citizens: “The state of osteonecrosis of the jaw related to BPs”
Sep. 2008 academic association A pamphlet, entitled “Bisphosphonates and osteonecrosis of the jaw: clinical manifestations and guidelines
for management, 2008”
Feb. 2009 academic association Training session for dentists, entitled “The state of osteonecrosis of the jaw related to BPs”
Feb. 2009 academic association News article, entitled “Bisphosphonates and osteonecrosis of the jaws”
May 2009 PMDA, academic association Announcement of a guidance publication, entitled “Bisphosphonate-Related Osteonecrosis of the Jaws”35
This official therapeutic manual for severe adverse reactions included the diagnostic criteria, clinical
manifestations, risk factors and management methods for iv and oral BP-related osteonecrosis of the jaw for
citizens and health care professionals
June 2009 academic association Public meeting for citizens, entitled “The state and the management of osteonecrosis of the jaws related to
BPs”
July 2009 academic association Training meeting regarding BP-related osteonecrosis of the jaw for health care professionals
Nov. 2009 academic association Publication of an observational study36
The follow-up survey showed that surgical treatment might be useful for BRONJ when performed at the
appropriate time, and BRONJ was shown to be refractory because only nine of 17 cases were cured in these 2
years.
May 2010 academic association,
pharmaceutical manufacturers
Publication of a position paper37
June 2010 PMDA Measure: revised package inserts for alendronate, risedronate and etidronate
“ONJ has been reported in patients receiving bisphosphonates, regardless of the route of administration.
Treating physicians should advise their patients to undergo dental examinations and to finish any invasive
dental procedures, such as tooth extraction, if necessary, prior to treatment with BPs. While on treatment with
BPs, these patients should have regular dental consultations and avoid invasive dental procedures.”
Sep. 2010 academic association Publication of a book, entitled “The utility and osteonecrosis of the jaw of BPs”
Sep. 2010 PMDA Release of safety measures (“The progress of assessments and measures regarding BP-related osteonecrosis of
the jaw”), including a survey of the number of cases of BP-related osteonecrosis of the jaw and an outline of
the individual case reports reported to PMDA
*The date indicates the first dissemination of safety information.
†PMDA: Pharmaceuticals and Medical Devices Agency.
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increased before 2006 and since then has remained
approximately constant.
The EMRs of a total of 1987 patients with records of
ONJ or inflammatory conditions of the jaw that were
possibly related to ONJ were manually reviewed, and
46 patients were confirmed to have ONJ.18
The incidence proportion of confirmed ONJ in the
BP group increased approximately four-fold in 2009
and 2010, compared with the pre-2009 level. The
incidence proportion of confirmed ONJ in the non-
BP group remained low (Figure 3a). Both of the
incidence proportion of confirmed ONJ cases and that
of inflammatory conditions of the jaw increased after
2009; however, the increase in inflammatory
conditions of the jaw was not as high as that of con-
firmed cases (Figure 3b). This measure was therefore
not a good surrogate for confirmed ONJ in this study.
DISCUSSION
Risk communication efforts by pharmaceutical
manufacturers and academic associations began within
1 year after the package insert was revised in October
2006, and ONJ was increasingly reported to the
PMDA within 1 year. In our cohort, the incidence
proportion of ONJ, diagnosed according to standard-
ized criteria, increased in 2009 and in later years.
During this period, BPs were frequently prescribed,
and there were no increases in the use of alternative
agents, such as selective estrogen receptor modulators.
Physicians’ case reports regarding ONJ in 20034,5 in
the USA led to revisions of package inserts in 2004 to
2005.7,25,26 In Japan, the pharmaceutical manufacturers
revised the package inserts for intravenous BPs in 2005
and for oral BPs in 2006 and 2007, but the revision was
delayed for 2 years after the revision in the USA. The
physicians’ case reports regarding ONJ were first
published in 2007, 4 years after their publication in the
USA; thus, the physicians’ reports in Japan did not
contribute to the increased suspicion of ONJ related to
BPs or to the revision of the package insert. Academic
associations were rather active in risk communication
in the later dissemination phase. Physicians and aca-
demic associations have been able to detect new safety
concerns for marketed drugs and to conduct epidemio-
logical studies effectively, and we should reconsider ac-
ademic associations, as well as the regulatory authority
Figure 1. Trends in the number of ONJ cases per year reported to the Drug Adverse Reactions Reporting System of the PMDA and risk communication
activities. Legend: The cases of ONJ that were suspected adverse reactions to oral bisphosphonates and those that were suspected adverse reactions to other
agents for osteoporosis, reported to the Drug Adverse Reactions Reporting System of the PMDA, are shown as a dark gray line and a light gray line, respec-
tively. Black arrowhead: risk communication from the PMDA; gray arrowhead: risk communication from pharmaceutical manufacturers; arrow: risk commu-
nication from academic associations
Figure 2. The number of patients prescribed each agent for osteoporosis
in the cohort. Legend: The numbers of patients prescribed bisphosphonates,
estrogen and a selective estrogen receptor modulator, as well as other
agents for osteoporosis, each year in a cohort of 6293 osteoporosis patients
are illustrated with a dark gray line of diamonds, a gray line of triangles and
a light gray line of squares, respectively. The year 2000 contains 2 months,
and the year 2010 contains 10months. The numbers of patients receiving
osteoporosis medications in each year are shown below the graph
risk communication and incidence proportion of osteonecrosis of jaw
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and pharmaceutical manufacturers, as resources for
monitoring and minimization of the risks of medicines
and for ensuring the accuracy of information.
We evaluated the impact of risk communications by
analyzing the prescriptions of medications for osteopo-
rosis and the incidence proportion of ONJ. The use of
BPs increased steadily, but the prescriptions for BPs
were not influenced by the risk communications in this
study. BPs are among the most established drug types
for the treatment of osteoporosis in postmenopausal
women,27 and the gradual increase in the use of BPs
over the periods, before and after the dissemination of
the safety information, was reasonable considering the
risk–benefit balance. We could not determine whether
the physicians prescribed BPs after considering the
risk–benefit balance or simply did not receive the safety
information. Many confounding factors can influence
the prescription of BPs, such as the active participation
of academic associations or the perceptions of
physicians and patients toward adverse events. Physi-
cians might hesitate to change prescribing habits be-
cause of known obstacles, such as the lack of time
during outpatient care and the desire to maintain trust
in the physician–patient relationship.28
Figure 3. (a). The incidence proportion of confirmed cases of ONJ in the cohort. Legend: The incidence proportions of the confirmed ONJ cases in 100 BP-
group patients in 2000–2002, 2003–2004, 2005–2006, 2007–2008 and 2009–2010 are indicated by a dark gray line of diamonds. The incidence proportions of
confirmed ONJ cases per 100 non-BP-group patients in each 2- to 3-year period are indicated by a light gray line of squares. The number of patients in the BP
group, the number of confirmed ONJ cases in the BP group, the number of patients in the non-BP group and the number of confirmed ONJ cases in the non-BP
group are shown below the graph. (b). The proportions of recorded ONJ cases in the cohort. Legend: The proportions of recorded cases of inflammatory con-
ditions of the jaw in 100 BP-group patients in 2000–2002, 2003–2004, 2005–2006, 2007–2008 and 2009–2010 are indicated by a dark gray line of diamonds.
The proportions of recorded cases of inflammatory conditions of the jaw in 100 non-BP-group patients in each 2- to 3-year period are indicated by a light gray
line of squares. The number of patients in the BP group, the number of recorded cases of inflammatory conditions of the jaw in the BP group, the number of
patients in the non-BP group and the number of recorded cases of inflammatory conditions of the jaw in the non-BP group are shown below the graph
e. sumi et al.
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The rapid increase in the cases of ONJ that were
suspected adverse reactions to oral BPs reported to the
regulatory authority after the risk communications efforts
might indicate that the primary cause of the increase was
awareness of the disease because the increase was quite
sharp. The incidence proportion of ONJ in the BP group
increased in our cohort, although the increase occurred 3
years after the risk communications began. There would
have been few missed or misdiagnosed cases of ONJ in
our cohort because the cases were diagnosed based on
an extensive manual review of the EMRs, using
well-established criteria. There might have been other
causes for the increase in the incidence proportion of
ONJ in our cohort in addition to risk communication;
one possibility is the longer exposure to BPs8,29 in the
cohort. Longer exposure and risk communication
occurred simultaneously; therefore, we could not distin-
guish the impact of risk communication from that of
longer exposure. There was a time difference between
the increase in the number of cases of ONJ reported in
the Drug Adverse Reactions Reporting System and the
increase in the incidence proportion of ONJ in the cohort.
The cases of ONJ reported to the Drug Adverse
Reactions Reporting System include past cases of ONJ:
cases that occurred before 2006 might be reported as
cases of ONJ after 2006. Moreover, the diagnosis of
ONJ is not standardized and might include other inflam-
matory conditions of the jaw. However, the number of
ONJ patients in the cohort reflects the number of active
ONJ patients diagnosed in the hospital. The difference
between the recording and the diagnosis of ONJ most
likely resulted in the time difference.
Previous reviews have found it difficult to estimate
the average effect of risk communication on clinical
practice16,17,30 because of heterogeneity in the study
designs, analyses, outcome measurements, therapeutic
areas and types of communication. ONJ can be reduced
with preventive measures, including clinical oral exam-
inations and good oral hygiene.31,32 Unfortunately, we
did not observe a decrease in the incidence proportion
of ONJ in our cohort during this study period, which
would have been the clinical outcome. Additional
appropriately designed research is warranted to under-
stand the effects of past communications strategies and
to estimate the impact of future communication.
The limitations of our study are described below.
First, factors other than safety information collected
in our study, such as pharmaceutical use, could have
simultaneously influenced the incidence proportion
of ONJ. Second, we did not consider the scale, the du-
ration or the content of the risk communication; it is
therefore not possible to evaluate the impact of each
risk communication material quantitatively. Third,
the data on drug use and on the incidence proportion
of ONJ in Kyoto University Hospital were limited to
a single institution in Japan; thus, the generalizability
of the results cannot be assured. The much higher inci-
dence of ONJ in our study compared to the published
literature might be explained by the inclusion of nu-
merous steroid users, older patients and inpatients.
Moreover, the cohort study was subject to a referral
bias toward the selection of more severe cases, given
that our department is the lead institution for oral and
maxillofacial surgery in Kyoto City, as discussed in
our previous report.18 We could not account for BP ex-
posure that occurred before consultation at Kyoto Uni-
versity Hospital, which might have affected the
incidence proportion of ONJ. Finally, this study was
retrospective, using a database derived from the
EMRs, and the data were not as accurate and consis-
tent as they would have been in a prospective study.
CONCLUSION
The use of oral BPs increased in osteoporosis patients,
regardless of the safety notifications concerning ONJ
related to BPs. ONJ was increasingly diagnosed after
the dissemination of safety information about BP-
related ONJ using repetitive and mixed communica-
tion methods; the impact of these communications
materials was not clear. Our evaluation of the risk
communication materials suggests that appropriate
cooperation models involving the parties concerned
with pharmacovigilance should be planned for the dissem-
ination of safety information and for the delivery and
evaluation of new safety concerns with marketed drugs.
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KEY POINT
• The use of oral bisphosphonates (BPs) in
osteoporosis patients has increased regardless of
safety concerns about osteonecrosis related to
BPs. Osteonecrosis of the jaw was increasingly
diagnosed after risk communication; however,
the impact of the risk communication was not
clear. Safety notifications were disseminated
diligently after the package insert was revised.
However, there was no surveillance for
osteonecrosis of the jaw before the revision.
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